FDA clears next-gen tattoo removal laser from Cynosure

Cynosure (NSDQ:CYNO) said today it won FDA 510(k) clearance for its 1064 nm PicoSure laser delivery system designed for tattoo removal.

The next-gen laser delivery system has improved multi-wavelength laser technology desighed to remove the “full color spectrum of tattoo inks” in less treatments than previous versions, the Westford, Mass.-based company said.

“PicoSure is widely recognized by aesthetic practitioners for its unsurpassed clinical efficacy and proven performance. Consumers simply know it works. With the FDA clearance of the 1064 nm Laser Delivery System we believe our picosecond technology has the broadest range of clearances on the market. The new 1064 nm wavelength builds on our aesthetic industry leadership and expands PicoSure’s versatility for tattoos, pigmentation and skin revitalization,” CEO Michael Davin said in a press release.

The newly cleared 1064 nm wavelength laser delivery system is designed for the removal of black and other dark ink tattoos, and is complimentary to the company’s existing Focus lens array and other nm wavelength systems. The system can also be used to treat a range of dermatologic conditions including rinkles, acne scars and pigmented lesions, Cynosure said.

The 1064 nm wavelength will be offered as an upgrade to existing PicoSure customers, with initial shipments expected in the 2nd half of 2016.

Last February, the FDA cleared Cynosure’s 532 nm laser delivery system for its PicoSure tattoo-removal technology platform.

The post FDA clears next-gen tattoo removal laser from Cynosure appeared first on MassDevice.

from MassDevice http://ift.tt/1s8dcVQ